Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dr. Reddy's Laboratories Ltd ADR (NY: RDY ) 78.36 +1.10 (+1.42%) Streaming Delayed Price Updated: 10:15 AM EDT, Oct 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 9,373 Open 77.80 Bid (Size) 78.30 (9) Ask (Size) 78.42 (9) Prev. Close 77.26 Today's Range 77.80 - 78.77 52wk Range 63.72 - 84.46 Shares Outstanding 166,301,231 Dividend Yield 1.25% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression October 09, 2024 Via AB Newswire Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma October 08, 2024 From Aurigene Oncology Limited Via Business Wire Performance YTD +10.63% +10.63% 1 Month -0.67% -0.67% 3 Month -0.48% -0.48% 6 Month +7.82% +7.82% 1 Year +16.28% +16.28% More News Read More Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries October 02, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories – Elliott Wave Technical Analysis September 20, 2024 Via Talk Markets Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? September 03, 2024 Via Investor's Business Daily Organon Stock Sees Relative Strength Rating Rise To 91 August 27, 2024 Via Investor's Business Daily Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal August 24, 2024 Via Talk Markets Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold August 20, 2024 Via Investor's Business Daily Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug August 20, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar July 29, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy’s Q1FY25 Financial Results July 27, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem July 10, 2024 Via MarketBeat Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? July 01, 2024 Via Chartmill Dr. Reddy's Labs Stock Sees Improved Technical Strength June 28, 2024 Via Investor's Business Daily Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M June 26, 2024 Via Benzinga Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities June 03, 2024 From Aurigene Pharmaceutical Services Ltd. Via Business Wire Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business June 26, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. June 03, 2024 Via Investor's Business Daily Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America May 28, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK May 21, 2024 From Alvotech Via GlobeNewswire RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 May 07, 2024 Via InvestorPlace Dr. Reddy’s Q4 & Full Year FY24 Financial Results May 07, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. May 03, 2024 From Dr. Reddy's Laboratories Ltd. Via Business Wire Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK March 19, 2024 From Dr. Reddy’s Laboratories Ltd. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
